Buserelyn

When ATH:
L02AE01

Characteristic.

The synthetic analogue of gonadotropin-releasing hormone.

Pharmacological action.
Antigonadotropnoe, anti-androgenic, antiestrogens, antitumor.

Application.

Gormonozawisimae prostate cancer stages III and IV (if necessary, inhibiting the production of testosterone in the testes); breast cancer in women with preserved menstrual cycle and the presence of estradiol receptor / progesterone; hormone-dependent pathologies of the reproductive system, due to absolute or relative giperestrogeniey (endometriosis, incl. before- and postoperative periods, hysteromyoma, endometrial hyperplasia); for ovulation induction in the treatment of infertility (in combination with gonadotropins) in vitro fertilization programs (IVF).

Contraindications.

Hypersensitivity.

Restrictions apply.

Obstruction of the urinary tract in history, metastases in the vertebral column — because of the risk of being crushed spinal cord as a result of the aggravation of the disease (prostate cancer) at the beginning of treatment.

Pregnancy and breast-feeding.

Contraindicated in pregnancy. At the time of treatment should abandon breastfeeding.

Side effects.

From the nervous system and sensory organs: headache (by intranasal administration), mood lability, sleep disturbance, depression, Symptoms of eye irritation (while wearing contact lenses).

From the digestive tract: change in appetite, nausea, vomiting.

With the genitourinary system: decreased libido, impotence, vaginal dryness, ovarian cysts, lower abdominal pain, menstrualnopodobnoe bleeding.

Allergic reactions: hives, dermahemia, angioedema.

Other: tides, irritation of the mucous membranes of the nose and nosebleeds (by intranasal administration), increased perspiration (by intranasal administration), acne, dryness of skin and mucous membranes, bone demineralization, gynecomastia, thrombosis, swelling of feet and ankles; symptoms, associated with higher levels of testosterone in the blood at the beginning of therapy (bone pain, numbness or tingling in the hands or feet, strangury, weakness in the legs).

Cooperation.

Concomitant use of other drugs, containing hormones (incl. gonadotropin — when the induction of ovulation), may contribute to ovarian hyperstimulation syndrome. Reduces the effect of hypoglycemic agents.

Dosing and Administration.

/ M, n / a, intranasally.

Hormone-dependent prostate cancer: / m, 3,75 mg once every 4 weeks or n/a on 0,5 mg 3 twice a day for 7 days, further supporting intranasal therapy at a dose 0,9 - 1,2 mg / day 4 introduction to disease progression.

Mammary cancer: intranasally, 0,9 mg / day 3 introduction.

Endometriosis, endometrial hyperplasia, hysteromyoma: / m, 3,75 mg once every 4 week for 4-6 months (myoma is within 3 months before surgery; When conservative treatment is 6 Months); treatment should begin in the first 5 days of the menstrual cycle. Intranasal 0,9 mg / day 3 introduction; Treatment starts at 1 or 2 day of the menstrual cycle, no more 6 Months (osteoporosis risk).

Treatment of infertility by IVF: / m, 3,75 mg once on the 2 day of the menstrual cycle or s /, 0,20.5 mg 1 once a day for 1-3 weeks prior to administration of hCG starting from 1 day or (the exclusion of pregnancy) from 21 day of the menstrual cycle (the maximum dose - 0,5 mg 2 once a day). Intranasal, 0,6 mg / day 4 administration over 1-3 weeks, beginning with 1 day, the exclusion of pregnancy — 21 day of the menstrual cycle before the introduction of CG. The maximum dose - 1,2 mg / day. Repeated courses under hormonal control and dynamic ultrasound monitoring.

Precautions.

Before initiation of therapy to rule out pregnancy and to stop taking oral contraceptives, during the first 2 months of treatment of endometriosis, endometrial hyperplasia and uterine fibroids need to use barrier methods of contraception (condoms).

Intranasal application on the background of rhinitis should be cleaned before the introduction of the nasal passages; Avoid the use of nasal vasoconstrictor drugs before and during the 30 minutes after administration of buserelin.

To apply caution in patients with depression.

For ovulation induction may be appointed only by a physician, with experience in the treatment of infertility.

Be wary of during the drivers of vehicles and people, activities are associated with high concentration of attention.

Cautions.

For the treatment of prostate cancer should not be given to patients after orchiectomy. At the beginning of treatment for prostate cancer may increase disease (usually less 10 days), associated with the initial transient increase in the concentration of androgens in the blood ("Flare phenomenon"). Thus possible severe pain in the bones or at the location of the tumor, exacerbation of symptoms (incl. dizurija). Strengthening of neurological disorders in patients with metastases in the spine can cause temporary weakness and paresthesias in the lower extremities. It should warn patients of the need for continued therapy, despite side effects, that during the further treatment are reduced or disappear.